Company / Cash & Equivalents
Pacira BioSciences, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$158.5M
FY2025
5-year range
$104.1M / $585.6M
FY2021-FY2025
Trend
-42.7%
vs FY2024
Sector context
#113 of 207
Health Care
What the data says
At $159M, Pacira BioSciences, Inc.'s cash & equivalents ranks #113 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $36M in FY2016 to $586M in FY2021.
Based on SEC 10-K filings.
$159M in FY2025 with a 5-year CAGR of +3.7%.
Improved from $153M to $159M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +15.0%
- 5-Year CAGR
- +3.7%
- 10-Year CAGR
- -
Sector benchmark
#113 of 207 in Health CareTop 55% of 207This company $158.5M Sector average $669.5M
▼
-76.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.7%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 42.7% year-over-year.
- Ranks #113 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $158.5M | -42.7% |
| FY2024 | $276.8M | +80.5% |
| FY2023 | $153.3M | +47.2% |
| FY2022 | $104.1M | -82.2% |
| FY2021 | $585.6M | +341.9% |
| FY2020 | $132.5M | +144.8% |
| FY2019 | $54.1M | -5.0% |
| FY2018 | $57.0M | +0.0% |
| FY2017 | $57.0M | +58.5% |
| FY2016 | $35.9M | -36.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026